AstraZeneca Acquires $160 Million Chinese Business from FibroGen to Expand Market Presence

On February 20, AstraZeneca announced its agreement to acquire the Chinese operations of FibroGen for approximately $160 million. This move follows AstraZeneca's acquisition in December 2023, but this time it involves a U.S.-based biotech company's operations in China, rather than a local innovator.

Under the terms of the agreement, FibroGen will receive $85 million in enterprise value along with around $75 million in cash held by FibroGen China, totaling about $160 million. The transaction is expected to close in mid-2025, pending customary closing conditions, including regulatory review in China.

Upon completion, AstraZeneca will gain full rights to Roxadustat in China, while FibroGen retains rights to the drug in the U.S. and other markets not licensed to AstraZeneca. Roxadustat is a flagship product for FibroGen, designed to treat anemia associated with chronic kidney disease.

Roxadustat has historical significance, having been developed through collaboration between FibroGen and AstraZeneca. Approved in China in December 2018, it became the world's first oral hypoxia-inducible factor prolyl hydroxylase inhibitor to launch, reversing the trend where most innovative drugs were first approved in Western markets before entering China.

AstraZeneca has already engaged in the commercialization of Roxadustat in China, where the drug has performed well, generating $284 million in sales in 2023, amounting to 2 billion yuan. However, the drug faces challenges from a "patent cliff," as July 2024 marks the expected launch of a generic version from Shiyao Group. Several other generic applications are currently under review.

One of AstraZeneca's key challenges will be extending the sales lifecycle of Roxadustat. FibroGen China is actively developing new indications for the drug, with a submission for treating chemotherapy-induced anemia already accepted by the Chinese regulatory authority.

AstraZeneca's General Manager for China, Lin Xiao, emphasized that this acquisition enhances the company's existing product portfolio in China and boosts its investment in the local pharmaceutical market. The company looks forward to regulatory decisions regarding Roxadustat for chemotherapy-related anemia in early 2025.